"Proto-Oncogene Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
| Descriptor ID |
D011518
|
| MeSH Number(s) |
D12.776.624.664.700
|
| Concept/Terms |
Proto-Oncogene Proteins- Proto-Oncogene Proteins
- Proto Oncogene Proteins
- Proto-Oncogene Products, Cellular
- Cellular Proto-Oncogene Products
- Proto Oncogene Products, Cellular
- Proto Oncogene Proteins, Cellular
- c-onc Proteins
- c onc Proteins
- Cellular Proto-Oncogene Proteins
- Cellular Proto Oncogene Proteins
- Proto-Oncogene Proteins, Cellular
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins".
This graph shows the total number of publications written about "Proto-Oncogene Proteins" by people in this website by year, and whether "Proto-Oncogene Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 7 | 0 | 7 |
| 1995 | 3 | 1 | 4 |
| 1996 | 6 | 1 | 7 |
| 1997 | 1 | 2 | 3 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 1 | 3 |
| 2002 | 3 | 2 | 5 |
| 2003 | 1 | 4 | 5 |
| 2004 | 1 | 7 | 8 |
| 2005 | 7 | 3 | 10 |
| 2007 | 2 | 1 | 3 |
| 2008 | 3 | 1 | 4 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 2 | 3 |
| 2011 | 3 | 1 | 4 |
| 2012 | 2 | 2 | 4 |
| 2013 | 4 | 2 | 6 |
| 2014 | 2 | 3 | 5 |
| 2015 | 1 | 1 | 2 |
| 2016 | 3 | 0 | 3 |
| 2017 | 1 | 0 | 1 |
| 2020 | 4 | 0 | 4 |
| 2021 | 2 | 0 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins" by people in Profiles.
-
Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications. Br J Cancer. 2024 Aug; 131(3):589-600.
-
Helicobacter pylori and Epstein-Barr Virus Coinfection Stimulates Aggressiveness in Gastric Cancer through the Regulation of Gankyrin. mSphere. 2021 10 27; 6(5):e0075121.
-
SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. Blood Cancer J. 2021 05 17; 11(5):93.
-
Upregulation of AXL and ß-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. Blood Cancer J. 2021 02 18; 11(2):37.
-
Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis. Target Oncol. 2020 10; 15(5):589-598.
-
A novel TLX1-driven T-ALL zebrafish model: comparative genomic analysis with other leukemia models. Leukemia. 2020 12; 34(12):3398-3403.
-
Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC. Mol Divers. 2021 May; 25(2):1091-1102.
-
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight. 2020 01 16; 5(1).
-
Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018 01; 17(1):39-49.
-
Mitochondrial BMI1 maintains bioenergetic homeostasis in cells. FASEB J. 2016 12; 30(12):4042-4055.